someone explain survodutide to me like I have not read a paper in years
someone explain survodutide to me like I have not read a paper in years. I am not trying to be the "source?" guy. I would just like a source. Assumed the weight numbers were the point and was corrected. They are secondary to what this is being developed for. Went slowly because everything published describes a…
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
Biopsy-confirmed population or imaging-selected?
MASH endpoints are histological, which is a much harder bar
That is an escalation schedule for an unapproved compound and this board does not host those.
independent testing on this compound is very thin
the titration in the trials was slow and deliberate
Same. Very thin independent data on this one, which should make everybody here more tentative than they are.
I would not read across from the obesity programmes. Different population, different endpoint, different question.
Correction: that is the imaging endpoint, not the histological one. The paper reports both and they differ substantially.
Phase 2 in a biopsy-confirmed population is a demanding design: recruitment is slow, the population is specific, and the results do not generalise to people who have not been characterised that way.
Agreed. The hepatic programme is the point of this compound and the weight discussion is a side effect of the side effect.